Mayo Clinic Study Assessed Impact of Neoadjuvant Chemoradiation in Patients with Unresectable Perihilar CCA

2022 Year in Review - Cholangiocarcinoma - Cholangiocarcinoma

The Mayo Clinic protocol is the standard to determine eligibility for liver transplantation and is based on strict selection criteria that include neoadjuvant chemoradiation before patients are eligible for liver transplantation. A multicenter retrospective study assessed whether survival outcomes associated with the Mayo Clinic protocol in patients with unresectable perihilar cholangiocarcinoma (CCA) were “truly due to the strict selection or due to the neoadjuvant chemoradiation,” per Flavio Rocha, MD, FACS, FSSP, Physician-in-Chief of the Knight Cancer Institute. Results from this study were shared at the 2022 International Hepato-Pancreato-Biliary Association World Congress.

In this international study, 2 centers in the Netherlands and France reviewed charts of 49 patients with unresectable perihilar CCA between 2011 and 2021 who were assessed with the Mayo Clinic selection criteria and stratified by neoadjuvant chemoradiation. The primary end point was overall survival; secondary end points included post-transplant morbidity and vascular complications.

Of the 49 patients who underwent liver transplantation, 27 received chemoradiation and 22 did not; median age was 55 years. In the cohort that received neoadjuvant chemoradiation (median follow-up of 25 months), 1-year survival rate was 65%, 3-year survival rate was 51%, and 5-year survival rate was 41%; the 1-year, 3-year, and 5-year survival rates of the cohort who had not received neoadjuvant chemoradiation were 91%, 68%, and 53%, respectively. The tumor 5-year recurrence rate was similar between the groups, 32% in the neoadjuvant chemoradiation cohort versus 53% in the cohort that did not receive chemoradiation. However, major vascular complications (defined as Clavien-Dindo >IIIa) were significantly higher in the chemoradiation group (41% vs 14%).

In summary, Dr Rocha stated, “This was an interesting analysis that looked at survival after liver transplantation in a very highly selected patient cohort. They found that there was no difference in survival between patients who had received neoadjuvant chemoradiation and those who had not; however, there was an increased rate of vascular complications in those that did have chemoradiation.”

He also noted, “The Mayo Clinic protocol has taken the test of time, and the chemoradiation piece does have significant treatment effect, with some folks even suggesting that the transplant is actually adjuvant therapy for chemoradiation. Although it is a hypothesis-generating approach, it is certainly food for thought, as we continue to evolve these transplant protocols on omitting chemoradiation.”

Sources: Hoogwater FJH, Kuipers H, de Meijer VE, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma: is neo-adjuvant chemo-radiation therapy really necessary? An international, multicenter comparison. International Hepato-Pancreato-Biliary Association World Congress 2022. Abstract FP16-4.

Van Keulen A-M, Olthof PB, Cescon M, et al. Actual 10-year survival after resection of perihilar cholangiocarcinoma: what factors preclude a chance for cure? Cancers (Basel). 2021;13:6260.

Related Items
Key Advances in the Treatment of Patients with BTC in 2023: New Targeted Therapies, Potential Biomarkers, and Combination Strategies
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
KEYNOTE-966: Pembrolizumab Combined With GemCis Versus GemCis Alone in Patients With BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Post-hoc Analysis of the ABC-01, -02, and -03 Trials in Patients With Advanced eCCA
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Efficacy and Safety of Tinengotinib in Patients With Advanced Refractory/Relapsed CCA Who Previously Received an FGFR Inhibitor
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
KLF5 Inhibition Reduces Tumor Growth and Sensitizes to Chemotherapy-Induced Cell Death in Experimental Models of CCA
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Phase 2 Trial of SHR-1316 Plus IBI310 in Patients With Advanced iCCA After Inadequate Response to First-Line Therapy
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Examination of Patients With CCA Treated With Novel Targeted Therapies After Extended Molecular Profiling on Liquid Biopsies
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Phase 2 Component of the BEER-BTC Study: Comparing Bevacizumab Plus Erlotinib Maintenance Versus Observation in Patients With Advanced BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
The DEBATE Trial: Neoadjuvant Durvalumab Plus GemCis Versus GemCis Alone for Patients With Localized BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
The Phase 2 ADJUBIL Study of Durvalumab Plus Tremelimumab With or Without Capecitabine in BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: